Odyssey Ther­a­peu­tics has pulled to­geth­er a nine-fig­ure pri­vate fund­ing round af­ter halt­ing its pub­lic mar­ket am­bi­tions ear­li­er this year.

The biotech raised $213 mil­lion from its ex­ist­ing in­vestors and a batch of new back­ers, more than it had ini­tial­ly sought, CEO Gary Glick told End­points News ahead of the com­pa­ny's an­nounce­ment Wednes­day.

The Se­ries D in­cludes first-time Odyssey sup­port­ers Affin­i­ty As­set Ad­vi­sors, Di­men­sion Cap­i­tal, Jeito Cap­i­tal, Light­speed Ven­tures, TPG Life Sci­ences In­no­va­tions and Wed­bush Health­care Part­ners. The Boston-based start­up has now raised more than $700 mil­lion when fac­tor­ing in part­ner­ships with Pfiz­er, John­son & John­son and Ter­ray Ther­a­peu­tics.

Avid­i­ty Bio­sciences' ex­on skip­ping drug for an un­com­mon form of Duchenne mus­cu­lar dy­s­tro­phy im­proved or sta­bi­lized func­tion­al out­comes at one year.

The Cal­i­for­nia biotech com­pa­ny pre­vi­ous­ly an­nounced that it was fil­ing for ac­cel­er­at­ed ap­proval with the FDA by the end of the year, and it hopes the new da­ta can bol­ster its case.

Avid­i­ty’s del-zo­ta is an ex­on 44 skip­ping treat­ment, which could be used for around 6% of peo­ple with Duchenne mus­cu­lar dy­s­tro­phy. In a Phase 1/2 tri­al and sub­se­quent ex­ten­sion study, Avid­i­ty fol­lowed 17 par­tic­i­pants for one year. Some ini­tial­ly re­ceived a 10 mg/kg reg­i­men while oth­ers re­ceived a 5 mg/kg reg­i­men, which is the dose that Avid­i­ty ad­vanced.

In an open-la­bel ex­ten­sion study, all pa­tients were giv­en the 5 mg/kg dose, which was ad­min­is­tered every six weeks, even if they re­ceived the high­er dose in the Phase 1/2 tri­al.

YolTech Ther­a­peu­tics, a pro­lif­ic Chi­nese biotech that’s al­ready be­gun test­ing four CRISPR gene edit­ing ther­a­pies in small clin­i­cal stud­ies, raised a $44.5 mil­lion Se­ries B to test sev­er­al more ge­net­ic med­i­cines in hu­mans and po­ten­tial­ly be­gin its first Phase 3 tri­al lat­er this year, it told End­points News in an ex­clu­sive in­ter­view.

The new round was led by the As­traZeneca-CI­CC Health­care In­vest­ment Fund, a $1 bil­lion eq­ui­ty fund es­tab­lished by the British phar­ma com­pa­ny and the Chi­na In­ter­na­tion­al Cap­i­tal Cor­po­ra­tion in 2019.

YolTech’s fund­ing comes amidst soar­ing at­ten­tion to Chi­nese biotech com­pa­nies, and as many US gene edit­ing com­pa­nies have cut staff and trimmed once-sweep­ing pipelines. And while some US gene edit­ing star­tups are just be­gin­ning — or still strug­gling — to test their first ther­a­pies in peo­ple, YolTech has wast­ed no time putting one ex­per­i­men­tal CRISPR ther­a­py af­ter an­oth­er in­to clin­i­cal tests.